Bottom line
- Total investment $227K – $496K including a $55K franchise fee.
- No Item 19 financial performance data disclosed — the franchisor chose not to publish revenue figures.
- Rated MODERATE with a risk score of 56/100. SBA loan default rate of 0.0% across 46 loans (below the industry average).
Item 1 · who you're contracting with
The Franchisor
Yale framework · single-unit ROIC
Returns Analysis
Pulls Item 7 (investment) and Item 19 (revenue) from this brand's FDD into the Yale unlevered-ROIC formula. Override any input to stress-test it against your own assumptions.
The model · Yale framework
What would one QC Kinetix® unit return on the cash you put in?
Unlevered ROIC · per unit
26%
Below typical band (30–60%)
Overview
About
QC Kinetix franchisees operate regenerative medicine clinics offering non-surgical joint pain treatments (PRP, stem cell therapy, etc.). Day-to-day operations include patient consultations, administering treatments, managing clinical staff, handling insurance billing, and maintaining regulatory compliance for medical procedures.
Item 7 · what it costs
The Vitals
Item 19
Financial Performance
This franchisor did not disclose financial performance representations in Item 19, or our extractor could not parse them.
Item 20 · unit dynamics
The Growth Chart
Year-over-year franchised unit counts and net change. Source: FDD Item 20.
Item 20 · 36 states with active franchisees
The Territory Map
Derived from franchisee contact records. Shows states with at least one current operator — not where the franchisor is registered to sell new units (that data is re-extracting in a future refresh).
States derived from franchisee phone area codes (Item 20). Approximate — ported numbers may show the original state, not the franchisee's current location.
Government records
SBA Loan Data
Aggregated from SBA 7(a) loan disclosures, public data unique to FranchiseVerdict.
FranchiseVerdict rating + FDD Items 3, 5, 6, 12, 17
Risk & Legal
QC Kinetix presents CAUTION-level risk: rapid unit growth masks absence of financial performance data, going concern ambiguity, and high capital requirements with unproven unit economics.
Score breakdown · what drove the 56 / 100 rating
- 01MEDNo average revenue or net income disclosed in FDD (Item 19 missing) — impossible to validate ROI claims or break-even timeline
- 02MINORExplosive unit growth of 178.9% YoY suggests either aggressive expansion or system instability — unsustainable growth often precedes contraction
- 03MINORHigh initial investment ($227K-$496K) combined with 8% royalty creates significant fixed costs with no proven unit economics
- 04HIGHGoing Concern flagged as 'False' — ambiguous disclosure suggests potential financial or operational stress at franchisor level
- 05MED169 units is still relatively small system — limited track record and higher franchisor dependency risk
- 06MINORProtected territory is positive, but without revenue data, territory value cannot be assessed
- 07MINORRoyalty structure (8% of gross weekly revenues) provides no incentive alignment if franchisee is unprofitable
Severity inferred from the FDD text · not a regulatory classification
FDD Items 5, 6, 12, 17 · continued from Risk & Legal
Contract & Territory Detail
Item 11
Training & Operations
Item 20
Franchisee Contacts
Phone numbers extracted directly from this brand's FDD Item 20. After purchase, you'll also receive a list of validation questions tailored to this brand.
Franchisee contacts
79 numbers
One-time purchase · CSV download · Validation questions included
FDD download
QC Kinetix® · FDD (2023) PDF